- Home
- BHF vs CELC Comparison
BHF vs CELC Comparison
Compare BHF & CELC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BHF | CELC |
|---|---|---|
| Founded | 2016 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Life Insurance | Medical Specialities |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.7B | 3.1B |
| IPO Year | N/A | 2017 |
Fundamental Metrics
Financial Performance| Metric | BHF | CELC |
|---|---|---|
| Price | $64.91 | $104.58 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 9 | 8 |
| Target Price | $58.88 | ★ $100.13 |
| AVG Volume (30 Days) | 868.1K | ★ 980.5K |
| Earning Date | 02-10-2026 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 14.74 | N/A |
| Revenue | ★ $7,830,000,000.00 | N/A |
| Revenue This Year | $40.59 | N/A |
| Revenue Next Year | $2.84 | N/A |
| P/E Ratio | $4.40 | ★ N/A |
| Revenue Growth | ★ 48.75 | N/A |
| 52 Week Low | $42.07 | $7.58 |
| 52 Week High | $66.33 | $112.64 |
Technical Indicators
Market Signals| Indicator | BHF | CELC |
|---|---|---|
| Relative Strength Index (RSI) | 61.12 | 61.67 |
| Support Level | $65.28 | $97.27 |
| Resistance Level | $65.51 | $112.64 |
| Average True Range (ATR) | 0.26 | 5.12 |
| MACD | -0.55 | -1.46 |
| Stochastic Oscillator | 36.48 | 34.59 |
Price Performance
Historical ComparisonAbout BHF Brighthouse Financial Inc.
Brighthouse Financial Inc is a United States-based provider of annuity products and life insurance through independent distribution channels and marketing arrangements with distribution partners. Its segments are Annuities, Life, Run-off and Corporate and Other. It derives a majority of the revenue from the Annuities segment which includes variable, fixed, index-linked, and income annuities. The life segment includes variable, term, universal, and whole life policies.
About CELC Celcuity Inc.
Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.